Tresca P - Search Results

1

[Study of vinorelbine (V) combined with hexamethylmelamine (H) (combination V-H) in adenocarcinoma of the ovary: results a phase I-IIA trial, NHO-88, of ARTAC "ovarian" group].

Pinon G, Pinel MC, Goudier MJ, Coiffier B, Filippi MH, Goupil A, Roullet B, Facchini T, Mignot L, Tresca P, et al. Pinon G, et al. Among authors: tresca p. Bull Cancer. 1991;78(12):1119-31. Bull Cancer. 1991. PMID: 1786425 French.

2

Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method.

Dieras V, Extra JM, Bellissant E, Espie M, Morvan F, Pierga JY, Mignot L, Tresca P, Marty M. Dieras V, et al. Among authors: tresca p. J Clin Oncol. 1996 Dec;14(12):3097-104. doi: 10.1200/JCO.1996.14.12.3097. J Clin Oncol. 1996. PMID: 8955654 Clinical Trial.

3

Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2.

Brain E, Isambert N, Dalenc F, Diéras V, Bonneterre J, Rezai K, Jimenez M, Mefti-Lacheraf F, Cottura E, Tresca P, Vanlemmens L, Mahier-Aït Oukhatar C, Lokiec F, Fumoleau P. Brain E, et al. Among authors: tresca p. Br J Cancer. 2012 Feb 14;106(4):673-7. doi: 10.1038/bjc.2011.591. Epub 2012 Jan 12. Br J Cancer. 2012. PMID: 22240778 Free PMC article. Clinical Trial.

4

An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Degardin M, Oliveira J, Geoffrois L, Rolland F, Armand JP, Bastit P, Chauvergne J, Fargeot P, van Glabbeke M, Lentz MA, Tresca P, Boudillet J, Fumoleau P, Cappelaere P. Degardin M, et al. Among authors: tresca p. Ann Oncol. 1998 Oct;9(10):1103-7. doi: 10.1023/a:1008446706578. Ann Oncol. 1998. PMID: 9834823 Free article. Clinical Trial.

5

Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients.

Schilling T, Fiebig HH, Kerpel-Fronius S, Winterhalter B, Variol P, Tresca P, Heinrich B, Hanauske AR. Schilling T, et al. Among authors: tresca p. Invest New Drugs. 1996;14(4):371-8. doi: 10.1007/BF00180813. Invest New Drugs. 1996. PMID: 9157072 Clinical Trial.

6

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours.

Eskens FA, Tresca P, Tosi D, Van Doorn L, Fontaine H, Van der Gaast A, Veyrat-Follet C, Oprea C, Hospitel M, Dieras V. Eskens FA, et al. Among authors: tresca p. Br J Cancer. 2014 Apr 29;110(9):2170-7. doi: 10.1038/bjc.2014.137. Epub 2014 Apr 8. Br J Cancer. 2014. PMID: 24714750 Free PMC article. Clinical Trial.

7

Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer.

Crown J, Kennedy MJ, Tresca P, Marty M, Espie M, Burris HA, DeSilvio M, Lau MR, Kothari D, Koch KM, Diéras V. Crown J, et al. Among authors: tresca p. Ann Oncol. 2013 Aug;24(8):2005-11. doi: 10.1093/annonc/mdt222. Ann Oncol. 2013. PMID: 23878115 Free article. Clinical Trial.

8

Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.

Pierga JY, Bidard FC, Cropet C, Tresca P, Dalenc F, Romieu G, Campone M, Mahier Aït-Oukhatar C, Le Rhun E, Gonçalves A, Leheurteur M, Dômont J, Gutierrez M, Curé H, Ferrero JM, Labbe-Devilliers C, Bachelot T. Pierga JY, et al. Among authors: tresca p. Ann Oncol. 2013 Dec;24(12):2999-3004. doi: 10.1093/annonc/mdt348. Epub 2013 Sep 6. Ann Oncol. 2013. PMID: 24013510 Free article. Clinical Trial.

9

Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.

Le Tourneau C, Diéras V, Tresca P, Cacheux W, Paoletti X. Le Tourneau C, et al. Among authors: tresca p. Target Oncol. 2010 Mar;5(1):65-72. doi: 10.1007/s11523-010-0137-6. Epub 2010 Apr 2. Target Oncol. 2010. PMID: 20361265 Review.

10

Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature.

Le Tourneau C, Razak AR, Gan HK, Pop S, Diéras V, Tresca P, Paoletti X. Le Tourneau C, et al. Among authors: tresca p. Eur J Cancer. 2011 Jul;47(10):1468-75. doi: 10.1016/j.ejca.2011.03.016. Epub 2011 Apr 7. Eur J Cancer. 2011. PMID: 21482105 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28 results

Search Page

Filters